帕利哌酮缓释片与奥氮平治疗精神分裂症的对照研究

摘要

目的 对比帕利哌酮与奥氮平治疗精神分裂症的效果.方法 将 70 例精神分裂症患者按随机数字表法分为 帕利哌酮缓释剂组和奥氮平组各 35 例.入组前未用抗精神病药物或停用抗精神病药物 2 周以上,分别使用帕利哌酮缓释剂 和奥氮平治疗,疗程均为 8 周.两组均采用阳性与阴性症状量表(PANSS)评定疗效,同时采用副反应量表(TESS)评定不良反 应.结果 两组疗效均显著,组间比较差异无统计学意义(P ＞0.05);帕利哌酮缓释剂组主要不良反应为椎体外系副反应 (EPS)、焦虑等,奥氮平组主要不良反应为心动过速、嗜睡等;帕利哌酮缓释剂组 EPS、失眠、焦虑发生率明显高于奥氮平组(P ＜0.05),心动过速、便秘、嗜睡、唾液增多明显低于奥氮平组(P ＜0.05).结论 帕利哌酮可作为精神分裂症的一线用药和维 持治疗用药.%Objective To compare the treatment effect of Paliperidone Extended-Release Tablets and Olanzapine for schizophrenia. Methods We randomly divided 70 schizophrenics (free of antipsychotics for more than 2 weeks) into two groups (35 cases in each group). One was treated with Paliperidone Extended-Release Tablets, the other with Olanzepine for 8 weeks. We assessed the curative effect of the two groups by Scale for the Assessment of Positive Symptoms and Scale for the Assessment of Negative Symptoms , and assessed the adverse reaction by the Side Effects Scale . Results There was no significant difference between the two groups in the treatment effect (P > 0.05). The adverse reaction of Paliperidone Extended-Release Tablets included extrapyramidal side effect ( EPS) , anxiety and so on. The adverse reaction of Olanzepine included tachycardia , somnolence, and saliva increase and so on. The incidence of EPS, somnolence and anxiety in patients with Paliperidone Extended -Release Tablets was significantly higher than that in those with Olanzapine ( P < 0.05 ) . Conclusion Paliperidone Extended -Release Tablets can be used in the first -line treatment and the maintenance treatment of schizophrenic .